[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 4739 Referred in Senate (RFS)]

<DOC>
116th CONGRESS
  1st Session
                                H. R. 4739


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                           December 10, 2019

Received; read twice and referred to the Committee on Homeland Security 
                        and Governmental Affairs

_______________________________________________________________________

                                 AN ACT


 
To amend the Homeland Security Act of 2002 to protect U.S. Customs and 
   Border Protection officers, agents, other personnel, and canines 
  against potential synthetic opioid exposure, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Synthetic Opioid Exposure Prevention 
and Training Act''.

SEC. 2. PROTECTION AGAINST POTENTIAL SYNTHETIC OPIOID EXPOSURE WITHIN 
              U.S. CUSTOMS AND BORDER PROTECTION.

    (a) In General.--Subtitle B of title IV of the Homeland Security 
Act of 2002 (6 U.S.C. 211 et seq.) is amended by inserting after 
section 415 the following new section:

``SEC. 416. PROTECTION AGAINST POTENTIAL SYNTHETIC OPIOID EXPOSURE.

    ``(a) In General.--The Commissioner of U.S. Customs and Border 
Protection shall issue a policy that specifies effective protocols and 
procedures for the safe handling of potential synthetic opioids, 
including fentanyl, by U.S. Customs and Border Protection officers, 
agents, other personnel, and canines, and to reduce the risk of injury 
or death resulting from accidental exposure and enhance post-exposure 
management.
    ``(b) Training.--
            ``(1) In general.--Together with the issuance of the policy 
        described in subsection (a), the Commissioner of U.S. Customs 
        and Border Protection shall require mandatory and recurrent 
        training on the following:
                    ``(A) The potential risk of opioid exposure and 
                safe handling procedures for potential synthetic 
                opioids, including precautionary measures such as the 
                use of personal protective equipment during such 
                handling.
                    ``(B) How to access and administer opioid receptor 
                antagonists, including naloxone, post-exposure to 
                potential synthetic opioids.
            ``(2) Integration.--The training described in paragraph (1) 
        may be integrated into existing training under section 411(l) 
        for U.S. Customs and Border Protection officers, agents, and 
        other personnel.
    ``(c) Personal Protective Equipment and Opioid Receptor 
Antagonists.--Together with the issuance of the policy described in 
subsection (a), the Commissioner of U.S. Customs and Border Protection 
shall ensure the availability of personal protective equipment and 
opioid receptor antagonists, including naloxone, to all U.S. Customs 
and Border Protection officers, agents, other personnel, and canines at 
risk of accidental exposure to synthetic opioids.
    ``(d) Oversight.--To ensure effectiveness of the policy described 
in subsection (a)--
            ``(1) the Commissioner of U.S. Customs and Border 
        Protection shall regularly monitor the efficacy of the 
        implementation of such policy and adjust protocols and 
        procedures, as necessary; and
            ``(2) the Inspector General of the Department shall audit 
        compliance with the requirements of this section not less than 
        once each year for the 5 years after the date of the enactment 
        of this section.''.
    (b) Clerical Amendment.--The table of contents in section 1(b) of 
the Homeland Security Act of 2002 is amended by inserting after the 
item relating to section 415 the following new item:

``Sec. 416. Protection against potential synthetic opioid exposure.''.

            Passed the House of Representatives December 9, 2019.

            Attest:

                                             CHERYL L. JOHNSON,

                                                                 Clerk.